Company RXi Pharmaceuticals Corp Nasdaq
Equities
US74979C3034
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 18/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 14/09/17 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 09/11/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 18/06/12 |
Director/Board Member | 73 | 01/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 17/04/13 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 06/06/17 |
Robert Ferrara
BRD | Director/Board Member | 73 | 30/09/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 4,591,700 | 4,564,638 ( 99.41 %) | 0 | 99.41 % |
Company contact information
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.comSector
1st Jan change | Capi. | |
---|---|---|
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+43.45% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- PHIO Stock
- Stock
- Company RXi Pharmaceuticals Corp